[Skip to Content]
[Skip to Content Landing]

COVID-19 Antibody Tests Perform Well in Head-to-Head Comparison

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Four widely used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests had high sensitivity and specificity in what scientists said was the first large head-to-head comparison of commercial immunoassays developed during the coronavirus disease 2019 (COVID-19) pandemic.

The study, funded by Public Health England and the UK National Institute for Health Research, assessed the performance of high-throughput immunoassays from Abbott, DiaSorin, Roche, and Siemens, as well as an Oxford University–developed test. Researchers evaluated the assays using the same set of adult blood samples, which included 976 prepandemic samples and 536 samples from patients with polymerase chain reaction–confirmed SARS-CoV-2 infection. Except for the DiaSorin assay, all the tests would have an error rate of less than 1% at a seroprevalence of 10%, the researchers reported in The Lancet Infectious Diseases.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Four widely used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests had high sensitivity and specificity in what scientists said was the first large head-to-head comparison of commercial immunoassays developed during the coronavirus disease 2019 (COVID-19) pandemic.

The study, funded by Public Health England and the UK National Institute for Health Research, assessed the performance of high-throughput immunoassays from Abbott, DiaSorin, Roche, and Siemens, as well as an Oxford University–developed test. Researchers evaluated the assays using the same set of adult blood samples, which included 976 prepandemic samples and 536 samples from patients with polymerase chain reaction–confirmed SARS-CoV-2 infection. Except for the DiaSorin assay, all the tests would have an error rate of less than 1% at a seroprevalence of 10%, the researchers reported in The Lancet Infectious Diseases.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close